Sansum Diabetes Research Foundation Using MNKD Drug for Juvenille Diabetes. Big News ! LINK
A service of the U.S. National Institutes of Health
Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp
This study is ongoing, but not recruiting participants.
Sansum Diabetes Research InstituteCollaborator:Juvenile Diabetes Research Foundation
Information provided by (Responsible Party):Sansum Diabetes Research Institute
Aegis Capital Reiterates Buy Rating, $35 PT on Amarin Corporation on FY2012 Financial Results
Dwight Einhorn, Benzinga Staff Writer
March 01, 2013
In a report published Friday, Aegis Capital reiterated its Buy rating and $35.00 price target on Amarin Corporation (NASDAQ: AMRN [FREE Stock Trend Analysis]).
Aegis Capital noted, “Yesterday afternoon, Amarin released 4Q and FY2012 financial results. The firm reported a net loss of $0.07 per share for 4Q 2012 and a net loss of $1.24 per share for FY 2012, vs. our estimate of a net loss of $0.30 per share for 4Q 2012 and a net loss of $1.51 per share for the full year. The improved bottom line was driven primarily by a higher-than-expected gain on change in fair value of derivative liability
Wedbush’s Christopher Marai and team:
We believe that the FDA’s guidance paves the way for accelerated approval (AA) of eteplirsen. The FDAguidance appears to us to offer a pragmatic approach to evaluating the safety and efficacy of compounds for the treatment of DMD, where endpoints are difficult, patients are few and no drugs currently exist…
2 Surging Biotech Stocks: Galena
Tom Meyer | More Articles
February 03, 2014
That recent slide represents an excellent opportunity for new investors to get in at an attractive valuation.
There are several reasons why the recent slide presents an attractive value point for new investors:
Pipeline Market Potential
When evaluating a small-cap biotechnology company such as Galena, investors should look at the potential
market size of the pipeline, the partnerships that the company has struck, and the balance sheet strength. Galena is excelling at all three of those components
Tesla Motors Upgraded to “Outperform” at Zacks (TSLA)
Posted by Logan Wallace o
Updated March 4, 2014
Zacks upgraded shares of Tesla Motors (NASDAQ:TSLA) from a neutral rating to an outperform rating in a report issued on Thursday, Stock Ratings News reports. They currently have $304.00 target price on the stock.Zacks’ analyst wrote, “We are raising Tesla Motors to Outperform based on its rising production and sales and rapid international expansion. The company has clinched a substantial share of the electric car market, thanks to an impressive product portfolio and a rapidly developing Supercharger network.
BioPharma Catalyst Trade Pick Of The Week: Biodel By: Scott Matusow
Biodel chose Eli Lilly's (LLY) Humalog as its comparator for BIOD-123 and in Phase I trials has shown very positive results. BIOD-123 showed a better pharmacokinetic profile (PK) than Humalog and an improvement in injection site tolerability - Humalog (along with Humilin) brings in yearly sales for Lilly of over $3.5B
THIS IS WHY GOOGLE GOING TO BUY VRNG-5 LINKS
Article " Case Upheld/Anyday Google Buys or Pays VRNG Billions. *link* 18-Aug-12 11:49 am
FIRST LINK COURT UPHOLDS VRNG CASE:
SECOND LINK VRNG TO BE BOUGHT OUT OR PAID BILLIONS BY GOOLE:
THIRD LINK: VRNG TO MAKE A BUNDLE
FOURTH ARTICLE :VRNG PRIMED TO GO HIGHER
Seeking Alpha 1/10/13
But most importantly we are achieving alignment with all the stakeholders in the DMD community, so we’ve been working with patient advocates with investigators who are experts in Duchenne, and we believe the FDA has really signaled in several ways their openness and willingness to consider accelerated approval and for other expedited paths to approval for these types of devastating illnesses and including in the rare disease space.
Seeking Alpha: Evans Capital
As the Facebook IPO nears there will be much attention to Renren. As I said in a previous article, the largest social network company in the world - Facebook - looks like it will be valued at $100 billion. Yet, Renren the largest social network company in China, the largest country in the world, trades at 1/100th of that not including its cash position? Based on those metrics alone, Renren should be trading at a higher premium from here. Add to that the growth both Renren is experiencing and the mobile internet growth China is experiencing, it is my opinion that Renren should at least be $20-$30 and as Facebook grows the valuation for Renren will also grow.
Go To Stocktwits, It will let you click and open link there.:
ASCO 50th Annual Meeting Science & Society 2014
Exhibitor List Booths
Celldex Therapeutics, Inc. 19127
Celldex Therapeutics, Inc. MR 15
The StreetInsider 8/8/13
Groupon (GRPN) Price Target Raised to $17 at Deutsche Bank; 'Almost Everything Accelerating'
Deutsche Bank maintained a Buy on Groupon, Inc. (NASDAQ: GRPN) and raised its price target of $17.00 (from $10.00). Analyst Ross Sandler thinks the story is 'crystallizing' and noted that "almost everything" is
This was copied and pasted from ACAD Homepage Website:
We hold worldwide rights to pimavanserin and have established a patent portfolio, which includes
numerous issued patents covering pimavanserin in the United States, Europe and several additional countries.
We believe that pimavanserin also has the potential to address a range of other neurological and psychiatric disorders that are under served by currently available anti psychotics and represent large unmet medical needs. This may include treatment for psychoses associated with other neurological disorders, including Alzheimer’s disease, and as a co-therapy for schizophrenia.
bought a ton
orphan status Valuable.
got in, this will be a media frenzy